Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,142.40
(
0.53%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.65
(
2.39%
)
Bitcoin
74,637.78
(
-0.28%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

zipjet

Send PM Follow Ignore
Followers 36
Posts 2637
Boards Moderated 0
Alias Born 10/06/2003

zipjet

Re: genisi post# 151628

Friday, 11/02/2012 8:09:44 AM

Friday, November 02, 2012 8:09:44 AM

Post# of 257253

Copaxone is still holding more than 40% of MS drugs market share.



It continues to be one of the top choices for new MS patients treated by the top* MS docs here. IMO, more people should be taking Tysabri.

I suspect it will take something very significant to upset the Copaxone share. BG12 IF priced close (unlikely) to Copaxone could do it.

ij



* Researchers and thought leaders.

It is astonishing what foolish things one can temporarily believe if one thinks too long alone ... where it is often impossible to bring one's ideas to a conclusive test either formal or experimental. J.M. Keynes

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now